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Abstract
Background: To determine if novel measures of cardiovascular health are associated with prevalence or
progression of age-related macular degeneration (AMD).
Methods: Measures of the cardiovascular system: included intima media thickness (IMT), pulse wave
velocity (PWV), systemic arterial compliance (SAC), carotid augmentation index (AI). For the prevalence
study, hospital-based AMD cases and population-based age- and gender-matched controls with no signs of
AMD in either eye were enrolled. For the progression component, participants with early AMD were
recruited from two previous studies; cases were defined as progression in one or both eyes and controls
were defined as no progression in either eye.
Results: 160 cases and 160 controls were included in the prevalence component. The upper two quartiles
of SAC, implying good cardiovascular health, were significantly associated with increased risk of AMD (OR
= 2.54, 95% CL = 1.29, 4.99). High PWV was associated with increased prevalent AMD. Progression was
observed in 82 (32.3%) of the 254 subjects recruited for the progression component. Higher AI (worse
cardiovascular function) was protective for AMD progression (OR = 0.30, 95%CL = 0.13, 0.69). Higher
aortic PWV was associated with increased risk of AMD progression; the highest risk was seen with the
second lowest velocity (OR = 6.22, 95% CL = 2.35, 16.46).
Conclusion: The results were unexpected in that better cardiovascular health was associated with
increased risk of prevalent AMD and progression. Inconsistent findings between the prevalence and
progression components could be due to truly different disease etiologies or to spurious findings, as can
occur with inherent biases in case control studies of prevalence. Further investigation of these non-invasive
methods of characterizing the cardiovascular system should be undertaken as they may help to further
elucidate the role of the cardiovascular system in the etiology of prevalent AMD and progression.
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Age-related macular degeneration (AMD) is the leading
cause of blindness in elderly Caucasians in the US [1],
Australia [2] and other industrialized nations. The preva-
lence of AMD rises dramatically with age; 27% of people
aged 90 and older have the more severe form of AMD [3].
With the anticipated increases in life expectancy, the inci-
dence of AMD will necessarily increase. It is therefore
important to identify risk factors for the disease with the
hope of identifying strategies for primary prevention.
Other than age, the most consistent risk factor that has
been identified for AMD is cigarette smoking [4]. It has
been estimated that 20% of blindness in adults may be
attributed to cigarette smoking [5]. Age and smoking are
also known risk factors for the development of cardiovas-
cular disease whilst other shared risk factors such as hyper-
cholesterolemia, high fat intake, and high body mass
index have been shown in some, but not all, studies to be
associated with AMD [6].
There have been a number of reports from case-control
and population-based cross-sectional studies on the asso-
ciation of cardiovascular disease parameters and AMD,
with inconclusive results [7-12]. In the prospective Beaver
Dam Eye Study, pulse pressure was modestly, but signifi-
cantly, related to the five-year incidence of retinal pigment
epithelial depigmentation and exudative macular degen-
eration [13] and higher pulse pressure and systolic blood
pressure were also related to the 10-year incidence of exu-
dative AMD [14]. Similar modest associations with pulse
pressure, systolic blood pressure and the five-year inci-
dence of AMD were observed in the Rottterdam Study
[15].
A vascular model for AMD has been proposed in which
lipid deposition in Bruch's membrane leads to increasing
stiffness, increasing post-capillary resistance of the choroi-
dal vasculature and elevated hydrostatic pressure of the
chorio-capillaris [16]. It was suggested that this combina-
tion of high choroidal capillary pressure, breaks in calci-
fied Bruch's membrane and vascular endothelial growth
factor leads to choroidal neovascularization.
To further investigate the possible association of AMD
with cardiovascular disease we took advantage of recent
work in the field of cardiovascular disease where alterna-
tive, novel, non-invasive techniques are being proposed as
robust measures of cardiovascular health. Whilst tradi-
tionally, brachial blood pressure (BP) has been used rou-
tinely as a screening test to assess central hypertension and
risk of cardiovascular disease, it may not be the best prog-
nostic parameter. Due to wave propagation phenomena
and changing arterial wall composition, brachial BP is not
identical to central aortic BP and it has been proposed that
central BP may be more causal in terms of cardiovascular
disease than brachial BP. Currently there is no overall
method of assessment of global arterial function, but
interest in this has been advanced by the availability of
non-invasive measures of hemodynamic variables such as
the arterial pressure waveform and volume flow. We
wished to take advantage of these novel techniques to
assess cardiovascular health in relation to prevalent AMD
and also the likelihood of progression of early AMD to
advanced disease.
Conduit artery (in particular aortic) mechanical proper-
ties are considered markers of vascular health, with
increased stiffness considered an indicator of a more del-
eterious state. Indeed these changes in the arterial
mechanical properties have been shown to bear a closer
relationship to chronological age than many other param-
eters like graying of hair and loss of skin elasticity [17].
Thus it has been proposed that the assessment of the bio-
logical as opposed to the chronological age of an individ-
ual's arteries may be of use in the management and
prevention of arterial disease. Large artery stiffness is
known to increase with age even in the absence of overt
cardiovascular disease. Aortic stiffness has a significant
impact on central systolic BP and can be indirectly meas-
ured by several non-invasive methods that assess different
aspects of large artery stiffness, such as pulse wave velocity
(PWV), systemic arterial compliance (SAC) and carotid
augmentation index (AI) [18-20].
With increasing intrinsic stiffening of elastic arteries there
is a decrease in their buffering ability and therefore a
resulting increase in pulse wave velocity (PWV). As central
BP measurements are not routinely available, PWV can be
considered an indirect marker. Specific studies have
related PWV to cardiovascular and all-cause morbidity
and mortality [20-25]. In the Cardiovascular Health and
Age-Related Maculopathy (CHARM) study population we
noted that brachial BP did not always predict PWV. Three
percent of subjects assigned as hypertensive using brachial
BP measurements had normal PWV whilst 18% of those
with abnormally high PWV, considered to have true cen-
tral hypertension, did not have abnormal brachial BP.
SAC reflects the function of an artery as a hollow recepta-
cle in its ability to expand to accommodate the pulsatile
blood flow [19] and associations have been found
between arterial compliance and aortic stiffness with cor-
onary artery disease [20]. SAC decreases as the arteries
stiffen and has been shown to be inversely related to
serum lipid levels [26].
Augmentation index (AI) is related to the timing of pres-
sure wave reflection with regard to generated left ventricu-
lar systolic pressure. AI is positively correlated with PWVPage 2 of 10
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[24]. AI increases with age and sedentary lifestyle and is
used as a surrogate measure of arterial stiffness.
Intima media thickness (IMT) quantification with B-
mode ultrasonography is a non-invasive technique to
identify and monitor preclinical atherosclerosis in large
artery walls, especially the carotid [27-29]. Increased IMT
is associated with increased risk of myocardial infarction
and stoke.
To our knowledge, there have been no studies of the
potential association of these novel cardiovascular health
measurements in determining the risk of prevalent AMD
or progression. Given that previous associations between
AMD and CVD have been inconsistent we wondered if
these newer measures of cardiovascular health would bet-
ter define the association between these two diseases.
Identification of modifiable risk factors for AMD would
have important implications for the management of the
disease prior to severe vision loss. The purpose of this
study was to determine if cardiovascular health, as deter-
mined by these novel non-invasive techniques, was asso-
ciated with prevalent AMD or AMD progression.
Methods
A detailed description of the methodology for the
CHARM (Cardiovascular Health &Age-Related Maculopa-
thy) Study has been published previously [30]. Study pro-
cedures were approved by the Human Research and Ethics
Committee at the Royal Victorian Eye and Ear Hospital
(project number 99/372H) and all participants gave writ-
ten informed consent prior to undergoing the examina-
tion. The research adhered to the tenets of the Declaration
of Helsinki.
Prevalent AMD Study Group
All participants with soft drusen or late stage AMD in the
AMD progression study (see next section for details) were
classified as cases for the study of risk factors for prevalent
AMD. Fifty-one additional cases of late stage AMD were
recruited from the Royal Victorian Eye and Ear Hospital
and a private retinal clinic in Melbourne. Age- and gender-
matched controls were recruited from the population-
based Melbourne Visual Impairment Project (VIP)
[2,3,31]. They had to be classified as controls at both the
baseline and five-year follow-up examinations for the VIP
to be classified as controls for the CHARM study. Subjects
with only pigmentary changes or intermediate drusen
were not included as either cases or controls. Subjects with
only hard drusen were classified as controls.
AMD Progression Study Group
Participants with documented AMD were recruited from
two previous studies after their completion: the Vitamin E
and Cataract and AMD (VECAT) Study [32-34] and the
MelbourneVIP[2,3,31]. In both studies AMD was classi-
fied from dilated fundus photographs using the Interna-
tional Classification and Grading System [35].
Intermediate drusen were included in the definition of
AMD, but small hard drusen in the absence of any other
AMD features were not classified as AMD.
The VECAT study was a randomized clinical trial, con-
ducted from 1994–1999, to assess the efficacy of 500 IU
of vitamin E versus placebo in preventing the incidence
and/or progression of cataract and AMD [31-33]. Com-
munity volunteers aged 55 to 80 years were recruited to
participate in the five-year VECAT study. At baseline, soft
drusen larger than 125 μm were found in 11.4% of the
study cohort, retinal pigment epithelium changes in 9.5%
and late stage AMD in 0.5% of participants [31]. The final
results showed no effect of vitamin E supplementation on
the incidence or progression of AMD [36], therefore there
should be no bias in the assessment of AMD progression
in this study cohort. Thus all of the participants with any
signs of AMD, excluding bilateral end stage disease, were
eligible for the CHARM Study.
The Melbourne Visual Impairment Project (VIP) was a
population-based study of the distribution and determi-
nants of eye disease in a random sample of permanent
Melbourne residents aged 40 years and older [2,3,34]. Eli-
gible residents were identified and recruited by household
census from nine randomly selected pairs of census dis-
tricts to participate in baseline assessments, conducted
between 1992–1994. The prevalence of early age-related
macular degeneration in the VIP was 14.9% in males and
15.2% in females, and the prevalence of late stage AMD
was 0.58% in males and 0.76% in females [3]. All availa-
ble VIP participants with AMD at baseline except those
with bilateral endstage disease were eligible to participate
in the CHARM study.
Recruitment for the CHARM Study commenced in 2000
and continued through 2002. Given the enrollment dates
for the VECAT and VIP studies, the follow-up time interval
for assessing AMD progression varied from six to ten
years.
Study Measures
The interviewer-administered questionnaire, based on the
VIP questionnaire, contained questions about personal
health history (including medication use), alcohol con-
sumption, smoking history, ocular sunlight exposure,
family history of AMD and blindness, quality of life, use
of exogenous hormones, cognitive function, and visual
function [34]. Dietary intake was assessed with a 4-page
self-administered, semi-quantitative food frequency ques-
tionnaire [37]. Uniocular distance visual acuity was testedPage 3 of 10
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lowed by objective refraction using Humphrey® Autore-
fractor (Humphrey® Instrument Inc, San Leandro,
California) and subjective refinement to determine the
best corrected visual acuity.
Height and weight were measured, as well as supine bra-
chial blood pressure, measured with a Dinamap device
(Critikon Vital Signs Monitor 1846 SX). Pulse pressure
(the difference between the measured systolic and diasto-
lic blood pressures) and heart rate were also measured.
Carotid scanning for the assessment of intima media
thickness (IMT) was assessed in supine subjects with a
Toshiba SSH-140A imaging unit (Toshiba Corporation,
Japan). Three longitudinal arterial images were taken at
the right and left sides of the common carotid, bulb and
internal carotid. The average IMT of the six far wall meas-
urements, all 12 walls, and the mean maximum of all sites
were calculated.
Details of the methods used to measure arterial structure
and function are described below. The methods and the
repeatability achieved by this group have been published
previously [38].
Systemic arterial compliance (SAC) was estimated using
the "area method" by obtaining a surrogate pressure
waveform representing the aortic root driving pressure via
applanation tonometry with a Millar Mikro-Tip pencil
type transducer (Millar Instruments Inc, Houston, USA).
Continuous wave Doppler velocimetry with a handheld
instrument (Multi Dopplex II, Huntleigh Healthcare) was
employed to assess flow in the ascending aorta. The mean
of 10 waves was used to determine representative SAC.
Carotid pressure waveforms obtained by applanation
tonometry were used to calculate the augmentation index
(AI), defined as the difference between the first and sec-
ond systolic peaks of the central arterial waveform,
expressed as a percentage of the pulse pressure. The mean
value from 10 pressure waves was taken as mean AI.
Pulse wave velocity (PWV) was measured by simultane-
ous recordings of arterial pressure waves at the right com-
mon carotid artery and the right femoral artery. Aortic
PWV in meters per second was calculated as transit dis-
tance divided by transit time.
The dilated ophthalmic examination included a slit lamp
examination and ophthalmoscopy with a 78 diopter lens.
Signs of AMD were graded. Stereo photos of the macula
were taken with a Zeiss FF4 camera. All the fundus photos
from the CHARM examination as well as the baseline
photos from the VIP and VECAT studies were graded by a
single trained, experienced photo grader. Ten percent of
the cohort was graded by another senior grader to ensure
consistency in grading. Any difficult photos were assessed
by the graders as well as a retinal specialist (RG).
The presence of AMD features was graded according to the
International Classification System [35,40]. Six levels of
AMD were scored: 1) no drusen or hard drusen only
(none in our study cohort), 2) intermediate drusen AND/
OR hyperpigmentation without hypopigmentation, 3)
distinct or indistinct soft drusen OR hypopigmentation
with or without hyperpigmentation, 4) distinct or indis-
tinct soft drusen AND hyper- or hypopigmentation, 5)
geographic atrophy, 6) neovascular AMD. The presence of
small hard drusen with no other features present was not
included in the definition of AMD. An increase in AMD
severity from level 2, 3 or 4 at baseline to one or more lev-
els in either eye, and also an increase of two or more steps
in the specific grades (as defined by the International
Classification and Grading System) [35,40] used to assess
size, total number, area occupied by a lesion and spread
to a more central location within a level, were defined as
progression. A comparison of the results of grading from
the three different cameras used in the VIP, VECAT and
CHARM studies revealed good agreement, with kappa val-
ues ranging from 0.69 to 0.90 for the various AMD fea-
tures [39,40].
Fasting blood samples were analyzed for blood glucose,
total blood cholesterol, high density lipoprotein (HDL)
cholesterol, low density lipoprotein (LDL) cholesterol,
fibrinogen, IgA, IgM, total white cells, lymphocytes, and
apolipoprotein E. Genomic DNA was isolated from
venous blood leukocytes using a standard phenol/chloro-
form extraction procedure [41]. The molecular techniques
used to genotype and score the ε2, ε3 and ε4 alleles of the
APOE gene have been described elsewhere [42]. Presence
of the ε4 allele was included as a covariate in the multivar-
iate models because of its proven association with cardio-
vascular disease and its protective effect on AMD which
has been shown in a number of studies [22,23]. We have
reported on the APOE gene effect on the CHARM cohort
where we found the ε4 allele to be protective against pro-
gression of AMD [42].
Interview data were entered directly into a Microsoft
Access database that contained internal consistency
checks as well as confirmation of responses given during
previous interviews. All other data were entered twice and
verified. Data were analyzed with SPSS®, version 15.0.
Univariate analyses consisted of chi-squared and t-tests.
Because frequency matching was used for controls rather
than one-to-one matching, simple logistic regression was
employed rather than conditional logistic regression.
Multivariable adjusted logistic regression models and
analysis of co-variance models were also conducted. A p-Page 4 of 10
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tivariable adjusted logistic regression models were
employed to evaluate the relationship of augmentation
index (AI), intima media thickness (IMT) and systemic
arterial compliance (SAC) to prevalent AMD. All models
included 'ever smoked' because of its known association
with AMD prevalence and cardiovascular risk factors and
outcomes, and mean arterial pressure because it was cor-
related with all of the independent variables (correlation
coefficients ranged from 0.10 to 0.44, p-values ranged
from 0.10 to < 0.001). The presence of an Apoε4 allele was
included because it has been shown to increase risk of
CHD and has been shown to be associated with AMD in
numerous studies. Other covariates were included in sen-
sitivity analyses because they were found to be signifi-
cantly correlated with the independent variables of
interest. Multivariable adjusted logistic regression analy-
ses were employed to assess the independent relationship
between four significant/borderline significant factors
and AMD progression. SAC was also included in a sensi-
tivity analysis because of the significant result observed
with prevalent AMD. Age, 'ever smoked' and Apoε4 geno-
type were included in all multivariate models. Other co-
variates that were included in the models for sensitivity
were selected because they were significantly correlated
with the independent variable of interest.
Results
Cardiovascular Disease and Prevalent AMD
There were 320 subjects available for the analysis of risk
factors for prevalent AMD (160 cases and 160 age- and
gender-matched controls). The frequency matching pro-
duced equivalent groups for analysis, as evidenced by
non-significant differences in demographic factors
between the two groups. The mean age of the study sub-
jects was 73.9 years (range 52–93 years) and 40.9% were
male. The 160 population-based controls included sub-
jects with no fundus abnormalities (n = 16) and many
subjects with hard drusen only (n = 136). Of the 160 AMD
cases, 26% had late stage AMD (geographic atrophy or
neovascular AMD) in one eye, whilst the remaining
(74.0%) had soft drusen in at least one eye.
Nearly 12% (n = 18) of the AMD cases reported a history
of AMD in their parents or siblings, compared with 2% (n
= 3) of controls (chi-squared = 12.04, p = 0.001). AMD
cases not more likely then controls to have ever smoked
(49.0% versus 44.6%, chi-squared = 0.63, p = 0.43).
Descriptive characteristics of the continuous cardiovascu-
lar measures and risk factors in cases and controls are
summarized in Table 1. In the univariate analyses of vari-
ables that are risk factors for CVD or were measures of car-
diovascular health, a lower AI, indicating healthier
cardiovascular function was found to be significantly
associated with AMD. (t = -1.93, p = 0.05).
In multivariate models adjusted for APOE4 allele and hav-
ing ever smoked (Table 2), the upper two quartiles of SAC,
implying good cardiovascular function, were significantly
associated with an increase in prevalent AMD (OR = 2.04,
95%CL = 1.05, 3.95 for quartile 3 and OR = 2.54, 95% CL
= 1.29, 4.99 for quartile 4) and the test for linear trend
between SAC and prevalent AMD was statistically signifi-
cant (Mantel Haenszel chi-squared = 4.73, p = 0.03).
Although not statistically significant, mean maximum
IMT, also showed a trend indicating that thicker, more dis-
eased vessels might protect from AMD. This protection
from AMD was also seen as a trend when the worst AI
quartile was compared to the best, but was not consistent
across all quartiles. Whilst a greater aortic PWV, indicative
of worsening risk of cardiovascular disease, was correlated
with increased risk of AMD, the greatest risk was in the
second lowest quartile, with risk then becoming relatively
less for the upper (worst) two quartiles of PWV. Sensitivity
analyses that incorporated other vascular factors associ-
ated with the independent variables of interest (glucose,
Table 1: Univariate comparison of cardiovascular measures and risk factors in prevalent AMD cases and controls
Variable AMD cases Mean (SD) Controls Mean (SD) t-test, p-value
Systemic arterial compliance (log) -0.58 (0.29) -0.63 (0.29) 1.605, 0.11
Augmentation index 15.43 (9.22) 17.60 (10.23) -1.93, 0.05
Pulse wave velocity, aortic 12.28 (4.15) 11.80 (4.16) 1.00, 0.32
Average IMT of 12 walls (log) -1.09 (0.066) -1.08 (0.060) -0.77, 0.44
Mean maximum IMT (log) -0.95 (0.081) -0.95 (0.072) 0.24, 0.81
Mean arterial blood pressure 100.4 (13.0) 101.0 (15.3) -0.39, 0.70
Total cholesterol 5.57 (1.01) 5.62 (1.03) -0.38, 0.70
HDL cholesterol 1.62 (0.48) 1.59 (0.50) 0.505, 0.61
LDL cholesterol 3.32 (0.87) 3.35 (0.92) -0.33, 0.74
Triglycerides (log) 0.22 (0.46) 0.25 (0.48) -0.60, 0.55
Heart rate 61.6 (10.1) 63.4 (11.0) -1.49, 0.14
Glucose (log) 1.66 (0.18) 1.66 (0.23) 0.06, 0.95
Fibrinogen 4.35 (0.88) 4.22 (0.94) 1.23, 0.22Page 5 of 10
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substantially alter these associations (data not shown).
The same trends reported in Table 2 were observed when
restricting the analysis to only the late stage AMD cases,
although these findings were not statistically significant
due to the smaller number of cases. As an example, for
SAC, the multivariate odds ratios were 1.23 (95% CL =
0.44, 3.44), 1.17 (95%CL = 0.41, 3.28) and 1.30 (95%
CL+0.43, 3.96) respectively for the three upper quartiles
in comparison with the lowest quartile.
Cardiovascular Disease and AMD Progression
In the cohort of 254 subjects recruited for the progression
component of the study, AMD progression was observed
in 82 (32.3%) individuals. The mean age of the subjects
whose AMD progressed was 76.0 years, compared with
73.1 for those subjects whose AMD did not progress (t-test
= -2.96, p = 0.004). The gender distribution was not sig-
nificantly different between progressed (47.1% male)
cases and non-progressed (46.3% male) controls (chi-
squared = 0.13, p = 0.911). Subjects whose AMD had pro-
gressed were significantly more likely to have ever been
smokers (59.8% versus 40.7%, chi-squared = 8.1, p =
0.004) and were significantly more likely to have a first
degree relative with AMD (9.9% versus 2.4%, Fisher's
exact p-value = 0.022).
Unadjusted comparisons of cardiovascular risk factors
revealed frankly significant or borderline significant dif-
ferences in AI (t = 2.576, p = 0.011), PWV (t = -1.53, p =
0.128), and mean maximum IMT (t = -1.40, p = 0.165)
between AMD progressors and non-progressors (Table 3).
After adjusting for age, ever having smoked and APOE4
allele status, a higher AI, or worsening cardiovascular
function was associated with reduced risk of AMD pro-
gression (OR = 0.54, 0.31 and 0.30 for the upper three
quartiles respectively in comparison with the lowest quar-
tile, Table 4). The aortic PWV results were similar to the
prevalence data. Risk of progression was associated with
the second lowest (or second healthiest) quartile of PWV,
becoming less as the PVW got progressively worse. (OR
6.22 in second quartile, compared to an OR of 3.36 in the
highest quartile). There were no significant associations
found between mean maximum IMT, SAC and risk of
AMD progression. Sensitivity analyses that included cardi-
ovascular factors such as cholesterol levels, glucose, heart
rate and mean arterial pressure, known to be associated
with the independent variables of interest did not mark-
edly change the results (data not shown).
Discussion
A number of studies have assessed the potential relation-
ship between traditional cardiovascular risk factors and
AMD prevalence, with primarily weak and inconsistent
findings [6]. We were unable to find an association
between traditional brachial blood pressure measure-
ments and either the prevalent or progressive AMD in the
present study. In this study we also sought to determine
whether novel, potentially more robust, methods to assess
Table 2: Multiple logistic regression analyses of cardiovascular risk factors and risk of AMD prevalence adjusted for ever having 
smoked and APOE4 allele status.
Cardiovascular risk factor Number (%) of cases Odds ratio 95% CL
Systemic arterial compliance*
Quartile 1 30 (19.4%) 1.0
Quartile 2 39 (25.2%) 1.92 0.09, 3.76
Quartile 3 42 (27.1%) 2.04 1.05, 3.95
Quartile 4 44 (28.4%) 2.54 1.29, 4.99
Augmentation index
Quartile 1 36 (23.4%) 1.0
Quartile 2 36 (23.4%) 0.71 0.37, 1.35
Quartile 3 41 (26.6%) 1.03 0.55, 1.90
Quartile 4 41 (26.6%) 0.60 0.33, 1.09
Pulse wave velocity (aortic)
Quartile 1 32 (21.3%) 1.0
Quartile 2 37 (24.7%) 1.60 0.81, 3.15
Quartile 3 41 (27.3%) 2.03 1.01, 4.09
Quartile 4 40 (26.7%) 1.84 0.88, 3.86
Mean maximum IMT
Quartile 1 40 (25.3%) 1.0
Quartile 2 37 (23.4%) 0.79 0.42, 1.50
Quartile 3 40 (25.3%) 0.94 0.49, 1.78
Quartile 4 41 (25.9%) 0.91 0.48, 1.74
*p-value for linear trend = 0.03
(significant factors in bold)Page 6 of 10
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relationship between cardiovascular health and AMD. AI
is determined by the magnitude and relative arrival time
of the reflected pressure wave relative to cardiac ejection.
As such it is determined by distance to the distal reflecting
site, itself affected by height and state of the peripheral
vasodilation as well as heart rate and average PWV in the
aorta. SAC provides the best estimate of cardiac afterload
and (probably) of coronary perfusion efficiency. PWV has
been shown to be the most robust indicator of overall
atherosclerotic burden and cardiovascular risk. We know
of no other study that has quantified arterial structure and
function using these novel measures of cardiovascular
health in relation to both prevalent and progressive AMD.
Contrary to expectations, this study has produced some
significant findings that would suggest that individuals
with healthier cardiovascular function are more at risk of
not only developing AMD, but also progressing to more
severe stages.
Individuals with greater systemic arterial compliance
(SAC), one indicator of better cardiovascular health, had
a higher rate of prevalent AMD. People with higher AI
(implying stiffer arteries), were less likely to show progres-
sion of their AMD. The results of the PVW in both the
prevalence and progression cohort showed similar inter-
Table 3: Univariate comparison of cardiovascular measures and risk factors in AMD progressors and non-progressors
Variable AMD progression Mean (SD) No AMD progression Mean (SD) t-test, p-value
Systemic arterial compliance (log) 0.30 (0.49) 0.29 (0.51) -0.583, 0.56
Augmentation index 13.57 (8.44) 16.71 (9.77) 2.576, 0.01
Pulse wave velocity, aortic 12.51 (4.24) 11.64 (3.95) -1.53, 0.13
Average IMT of 12 walls (log) 0.08 (1.16) 0.08 (1.17) -0.491, 0.62
Mean maximum IMT (log) 0.12 (1.20) 0.11 (1.21) -1.396, 0.17
Mean arterial blood pressure 99.83 (12.78) 99.93 (12.04) 0.06, 0.95
Total cholesterol 5.55 (0.91) 5.50 (1.00) -0.319, 0.75
HDL cholesterol 1.57 (0.44) 1.54 (0.45) -0.607, 0.55
LDL cholesterol 3.31 (0.80) 3.34 (0.83) 0.285, 0.78
Triglycerides (log) 1.33 (1.61) 1.29 (1.62) -0.426, 0.67
Heart rate 64.1 (9.01) 62.3 (10.74) -1.39, 0.17
Glucose (log) 5.31 (1.22) 5.16 (1.19) -1.127, 0.26
Fibrinogen 4.20 (0.86) 4.12 (0.76) -0.715, 0.48
Table 4: Multiple logistic regression analyses of cardiovascular risk factors and risk of AMD progression adjusted for age, APOE4 status 
and having ever smoked.
Cardiovascular risk factor Number (%) of cases Odds ratio 95% CL
Systemic arterial compliance
Quartile 1 18 (21.7%) 1.0
Quartile 2 20 (25.2%) 1.18 0.53, 2.61
Quartile 3 18 (21.7%) 1.13 0.50, 2.55
Quartile 4 23 (27.7%) 1.80 0.80, 4.04
Augmentation index
Quartile 1 30 (38.4%) 1.0
Quartile 2 21 (26.9%) 0.54 0.26, 1.16
Quartile 3 14 (17.9%) 0.31 0.14, 0.70
Quartile 4 13 (16.7%) 0.30 0.13, 0.69
Pulse wave velocity (aortic)*
Quartile 1 7 (9.1%) 1.0
Quartile 2 26 (33.8%) 6.22 2.35, 16.46
Quartile 3 21 (27.3%) 3.69 1.38, 9.89
Quartile 4 23 (29.9%) 3.36 1.24, 9.06
Mean maximum IMT
Quartile 1 14 (17.1%) 1.0
Quartile 2 19 (23.2%) 1.26 0.54, 2.92
Quartile 3 25 (30.5%) 1.77 0.78, 4.01
Quartile 4 24 (29.3%) 1.34 0.57, 3.17
*p for linear trend = 0.008, **p for linear trend = 0.04
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cardiovascular disease) did appear to be associated with a
higher rate of prevalent AMD and a greater likelihood to
progress, as PWV got progressively greater, the increased
risk seen in the second best quartile of PWV lessened.
Considering that these cohorts, particularly the progres-
sion cohort were healthy volunteers, we may have seen
this trend continue if people with worse CVD were
included.
This same CHARM cohort has been assessed to find risks
for progression that are consistent with the literature in
terms of age, smoking, and the APOE gene risk [41]. We
are therefore confident that our cohort and our analysis of
AMD and its progression are robust. These surprising find-
ings may go some way towards explaining the inconsist-
encies found in the numerous studies reporting on
cardiovascular disease and AMD. Of course, we cannot
rule out the possibility that the findings are spurious.
Although this was a study of progression and prevalent
AMD, comparison of results from studies of incidence and
prevalence often result in discrepant findings, potentially
because of the many potential biases (such as recall bias)
inherent in case/control studies of prevalent disease. Also,
prevalent cases likely have better cardiovascular health
than the general population because they were still alive
to participate in the study. Although the participation
rates of the two source studies, the VECAT and the VIP,
were quite high, it is possible that the eye and/or cardio-
vascular health of the participants were significantly dif-
ferent to the non-participants. We have no data about the
non-participants for comparison to assess this potential
bias. Another potential bias and limitation in our study
design is the fact that the cardiovascular measures were
done at follow-up for the progression component of the
study. Subjects with poorer cardiovascular health could
have died between the baseline assessment of AMD status
and the follow-up visit to categorize AMD progression
and cardiovascular health. These potential biases and lim-
itations may all have affected the results to some degree
that is not possible to quantify.
Based on our results, we hypothesize that a reasonably
healthy cardiovascular system is necessary to drive the
processes that lead to the development and progression of
AMD. This would be consistent with the general clinical
observation that most people with AMD do not appear to
be vasculopaths. This concept is not new in retinal dis-
eases, for in diabetic retinopathy an eye is protected by
carotid disease, and is put at increased risk when the
carotid disease is repaired at surgery [47,48]. The counter-
intuitive finding of a protective effect of poorer cardiovas-
cular health on the prevalent AMD and progression of
AMD has some parallels in the genetics of AMD where the
Apo e4 allele has been shown in numerous studies to be
protective for AMD, yet is a risk factor for CVD and CVD
mortality.
Our non-significant findings for a potential relationship
between IMT and AMD are similar to those observed in
the Cardiovascular Health Study and differ from the 2.5-
fold increased risk of prevalent AMD that was found with
common carotid plaques in the Rotterdam Study. In this
latter study, carotid wall thickness was also found to be
significantly associated with incident AMD, although the
association was much weaker (OR = 1.15) and therefore
of questionable clinical significance. Those with plaques
(advanced disease) had increased rate of prevalent AMD,
whilst those with intermediate stages of CV disease
(increased IMT without plaque) had increased incidence.
This is compatible with our findings for incidence (SAC,
PWV) and prevalence (PWV, AI).
Our results, whilst initially surprising, might be explained
as follows if they are true. An individual requires reasona-
ble cardiovascular health (higher SAC, lower AI, lower
PWV) to be susceptible to AMD development. Develop-
ment and progression may commence alongside worsen-
ing arterial function (i.e. increasing AI, PWV and
decreasing SAC). It is well known that in survivors, arterial
stiffness plateaus with age, consistent with irreversible
structural changes. Our results suggest that those who
have reached this stage of maximal stiffening are protected
from both incident cases in those that do not already have
AMD, or further progression if they already have the dis-
ease.
The elderly with high SAC were more likely to have AMD.
The association of a requirement for good indices of car-
diovascular function to get AMD may be a result of those
with such indices surviving long enough, or may be indic-
ative of a direct causal effect. The first quartile of the PWV
group, those who are most "well" in a cardiovascular risk
sense, do not exhibit significant systemic atherosclerosis.
Moderate stiffening (second quartile group) are those
with worsening arterial function but does not include
those individuals who have already achieved their "worst
state". Those in the fourth quartile have plateaued and can
get no stiffer in terms of arterial structure-function.
Conclusion
Further investigation of these novel, non invasive tech-
niques of assessing the cardiovascular system seems war-
ranted as they may not only uncover further modifiable
risk factors, but may go some way to increase our under-
standing of the pathogenesis of AMD and its progression.
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